Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Future Med Chem ; 15(16): 1469-1489, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37650735

ABSTRACT

Background: Chagas disease is a life-threatening illness caused by Trypanosoma cruzi. The involvement of serine-/arginine-rich protein kinase in the T. cruzi life cycle is significant. Aims: To synthesize, characterize and evaluate the trypanocidal activity of diamides inspired by kinase inhibitor, SRPIN340. Material & Methods: Synthesis using a three-step process and characterization by infrared, nuclear magnetic resonance and high-resolution mass spectrometry were conducted. The selectivity index was obtained by the ratio of CC50/IC50 in two in vitro models. The most active compound, 3j, was evaluated using in vitro cytokine assays and assessing in vivo trypanocidal activity. Results: 3j activity in the macrophage J774 lineage showed an anti-inflammatory profile, and mice showed significantly reduced parasitemia and morbidity at low compound dosages. Conclusion: Novel diamide is active against T. cruzi in vitro and in vivo.

2.
Chem Biodivers ; 16(11): e1900359, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31544347

ABSTRACT

The objective of this study was to evaluate the chemical composition, and the trypanocidal and antibacterial activities of the essential oils from four species of Annonaceae: Bocageopsis multiflora (Mart.) R.E.Fr., Duguetia quitarensis Benth., Fusaea longifolia (Aubl.) Saff., and Guatteria punctata (Aubl.) R.A.Howard. The chemical composition of the essential oils from the aerial parts yielded 23, 20, 21 and 23 constituents, respectively, which were identified by GC/MS. The trypanocidal activity was evaluated against the amastigote and trypomastigote forms of T. cruzi. The antibacterial activity was evaluated by the microdilution method against enterohemorrhagic Escherichia coli, Pseudomonas aeruginosa, Streptococcus mutans, Streptococcus pyogenes, and methicillin-resistant Staphylococcus aureus. The results of trypanocidal activity showed that the essential oils of the four species were active at the tested concentrations, with G. punctata essential oil being the most active, with IC50 =0.029 µg/mL, and selectivity index (SI)=32, being 34 times more active than the reference drug benznidazole. All EOs showed strong antibacterial activity (minimum inhibitory concentrations of 4.68-37.5 µg/mL) against strains of S. mutans.


Subject(s)
Annonaceae/chemistry , Anti-Bacterial Agents/pharmacology , Oils, Volatile/pharmacology , Trypanocidal Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/isolation & purification , Escherichia coli/drug effects , Methicillin-Resistant Staphylococcus aureus/drug effects , Microbial Sensitivity Tests , Oils, Volatile/chemistry , Oils, Volatile/isolation & purification , Parasitic Sensitivity Tests , Pseudomonas aeruginosa/drug effects , Species Specificity , Streptococcus mutans/drug effects , Streptococcus pyogenes/drug effects , Trypanocidal Agents/chemistry , Trypanocidal Agents/isolation & purification , Trypanosoma cruzi/drug effects
3.
Am J Trop Med Hyg ; 97(5): 1289-1303, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29016289

ABSTRACT

Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a broad range of triatomines and mammalian species, including man. It afflicts 8 million people in Latin America, and its incidence is increasing in nonendemic countries owing to rising international immigration and nonvectorial transmission routes such as blood donation. Since the 1960s, the only drugs available for the clinical treatment of this infection have been benznidazole (BZ) and nifurtimox (NFX). Treatment with these trypanocidal drugs is recommended in both the acute and chronic phases of CD. These drugs have low cure rates mainly during the chronic phase, in addition both drugs present side effects that may result in the interruption of the treatment. Thus, more efficient and better-tolerated new drugs or pharmaceutical formulations containing BZ or NFX are urgently needed. Here, we review the drugs currently used for CD chemotherapy, ongoing clinical assays, and most-promising new experimental drugs. In addition, the mechanism of action of the commercially available drugs, NFX and BZ, the biodistribution of the latter, and the potential for novel formulations of BZ based on nanotechnology are discussed. Taken together, the literature emphasizes the urgent need for new therapies for acute and chronic CD.


Subject(s)
Chagas Disease/drug therapy , Chagas Disease/epidemiology , Nifurtimox/therapeutic use , Nitroimidazoles/therapeutic use , Trypanocidal Agents/therapeutic use , Animals , Chronic Disease , Clinical Trials as Topic , Disease Models, Animal , Drug Compounding , Humans , Incidence , Latin America/epidemiology , Nanoparticles/chemistry , Nifurtimox/pharmacokinetics , Nitroimidazoles/pharmacokinetics , Observational Studies as Topic , Randomized Controlled Trials as Topic , Tissue Distribution , Trypanocidal Agents/pharmacokinetics , Trypanosoma cruzi
SELECTION OF CITATIONS
SEARCH DETAIL
...